



March 25, 2015

Quotient Appoints Dr. Roger Dodd as Senior Scientific Advisor to the Donor Disease Screening Development Team for MosaiQ(TM)

JERSEY, Channel Islands, March 25, 2015 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the appointment of Dr. Roger Dodd as Senior Scientific Advisor to the Company's development team for the MosaiQ™ donor disease screening consumable. Dr. Dodd recently retired from the American Red Cross (ARC) after more than four decades of influential service. His research into infectious diseases is well known throughout the global blood banking industry and includes crucial studies supporting ARC's implementation of hepatitis B virus (HBV) surface antigen and human immunodeficiency virus (HIV) donor testing programs. In this new role, he will support the Quotient development team working on the donor disease screening consumable, advising on assay selection and the design and implementation of programs for internal validation and field trials in support of regulatory filings. In addition, Dr. Dodd will advise the Company on future applications of MosaiQ™ related to the detection of infectious diseases.

"I am pleased to announce the appointment of Roger Dodd as Senior Scientific Advisor to Quotient," commented Paul Cowan, Chairman and CEO of Quotient. "Dr. Dodd has dedicated a long and distinguished career exclusively toward the reduction of transfusion-transmitted infections and is considered one of the world's greatest contributors to blood transfusion safety. He will be a valuable member of our team as we complete development of the MosaiQ™ donor disease screening consumable and advance it through the regulatory process."

Dr. Dodd, 71, served as Vice President, Research and Development, and Director, American Red Cross Holland Laboratory from 2005 to 2014, retiring in October 2014. He obtained his BSc in biochemistry at the University of Sheffield in 1964 and worked as a Scientific Officer in the UK Ministry of Defence for six years. In 1970, Roger left for the United States to join the American Red Cross, where he worked for the next 44 years conducting groundbreaking research on transfusion-transmitted infections. During that time, he obtained his PhD in Microbiology at George Washington University in 1978. He has been credited in over 200 research publications and has edited three books on transfusion-transmitted infections. Dr. Dodd has been an Advisor to the World Health Organization (WHO) and President of the American Association of Blood Banks (AABB). He has also served as Chair of the Global Collaboration on Blood Safety. He received the Morten Grove-Rasmussen and Emily Cooley Memorial Awards from the AABB, a Tiffany Award from the American Red Cross and the John Snow Award from the American Public Health Association. Dr. Dodd currently serves on the Editorial Boards of Transfusion and Transfusion Medicine. He was elected to the position of Vice President on the ISBT Board in 2010 and currently serves as Secretary General.

About Quotient Limited

Quotient Limited ("Quotient") is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests, currently focused on blood grouping and serological disease screening. Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by any commercially available transfusion diagnostic instrument platform. The company's operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins, Switzerland.

CONTACT: Paul Cowan,

Chairman & Chief Executive Officer

paul.cowan@quotientbd.com

+41 79 128 6908

Source: Quotient Biodiagnostics, Inc.

News Provided by Acquire Media